Objective\ To exam the expression and the distribution of the aromatase mRNA in the brain of the mouse. Methods\ RNA dot\|blotting as well as in situ hybridization technique were used. Results\ (1)There were aromatase specific mRNA expression in the brain tissue during the period from E16 to P300,the highest levels of mRNA were detected at postnatal 6 days,and the lowest levels were found at adulthood.(2)The location of the aromatase mRNA was confined to neuronal(but not glial)cell bodies and their processes.(3)The mainly distribution of aromatase mRNA was detected in the regions of the cerebral cortex,thalamus,hypothalamus and limbic system.Many heavily labeled cells were found in the layer of pyramidal cells of cerebral cortex,medial preoptic area.medial septal nucleus,pyramidal layer of hippocampus,amygdaloid nuclei.cingulate cortex,piriform cortex and periamygdaloid cortex.The moderately dense signal was present in several thalamic and hypothalamic nuclei such as ventromedial nucleus,ventrolateral nucleus,laterodorsal thalamic nucleus,paraventricular nucleus,etc. Conclusion\ There was relationship between the gene expression of aromatase with the development of brain,there was good agreement between the distribution of aromatase mRNA and aromatase activity as previously reported.The high levels of aromatase mRNA in the region of hippocampus and cerebral cortex suggested that aromatase may implicate for sex dimorphism in cognition as well as learning and memory.\;

Objective To analyse effect of different dose of sustained-release theophyline on prealbumin, C-reactive protein and white blood cell count in patients with pediatric asthma.Methods 58 children with acute asthma attack in our hospital were collected.All children were randomly divided into high dose group and low dose group,29 cases in each group.On the basis of conventional treatment, high dose group were treated with high dose theophylline sustained release tablets 5 mg/kg, one times per eight hours,orally,and low dose group was treated with low dose theophylline sustained release tablets,2 mg/kg, one times per eight hours,orally.Two groups were treatment for two weeks.After the treatment, the serum levels of pre albumin, C-reactive protein and veinal blood level of white blood cell count were detected in all children.Results Compared with high dose group post-treatment, the serum level PA was higher in low dose group (P<0.05);the serum level of CRP was lower in low dose group (P<0.05);the veinal blood level of WBC, percentage of neutrophils and percentage of eosinophils was lower in low dose group (P<0.05) .Conclusion Compared with high dose of sustained-release theophyline,the low dose of sustained-release theophyline can significantly reduce the serum CRP level and veinal blood level of WBC, percentage of neutrophils and percentage of eosinophils, improve serum PA level in patients with pediatric asthma, reduce inflammation in patients.

Compared to portal vein embolization and traditional two-stage hepatectomy,associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) can induce the proliferation of liver rapidly,concomitantly with high incidence of complications and mortality in the perioperative period.The feasibility and safety have been improved gradually as the improvement of technology and the accumulation of experience.But it is still controversial on its efficacy for malignant tumors,especially with insufficiency of medium-and long-term out-comes.The mechanism of rapid proliferation induced by ALPPS needs more studies with further steps.

Objective To explore the gene expression of aromatase and estrogen receptor (ER-?) in malignant glioma cell line SHG-44. Methods Cell culture, immunocytochemistry, in situ hybridization and RT-PCR techniques were used. Results Aromatase and estrogen receptor gene expressions were detected in SHG-44 cells.The aromatase gene in these cells was expressed by means of the multi promoters (1^3, 1^4 and P Ⅱ).Conclusion It may provide some new data for the hormone regulation in carcinoma of nerve system.

Objective To explore the effect and adverse reaction of topiramate(TPM) on treating Lennox-Gastaut syndrome(LGS)(including therapeutic alliance or single ). Methods Twenty-four cases with LGS whose attacks could not be controlled by re-(gular) therapy were selected.TPM was gradually increased from low dosage till its showing effect or untolerant adverse reaction.Results Two cases were excluded because of adverse reaction and increase of attacks. The remained cases were followed up from 6 months to 15 months (average: 9 months). The total effective rate was 82.6%, 11 cases accounting for 45.8% free of attack. The tonic-clonic seizure reduced more than 50% accounting for 82.2%, the full control accounting for 66.7%. The myoclonic seizure reduced more than 50% accounting for 81.8%,the full control accounting for 58.8%.The atypical absence seizure reduced more than 50% accounting for 81.8%, the full control accounting for 63.6%. The maximum effect occurred about 2-40 weeks following TPM used, the dosage about 2-10 mg/(kg?d).The adverse reaction included anorexia (8 cases), language disorder (5 cases), drowsiness (4 cases), decrease of anamnesis (3 cases), weight loss or unchanged(3 cases), inattention (3 cases), depression (3 cases), mental bradypraxia (2 cases ), skin damage (1 case), stupor (1 case), gross hematuria(1 case).The hepatic and renal function were normal during therapy. Conclusion TPM is a new, broad-spectrum, effective and safe antiepileptics drug on treating LGS.

China ; Disasters ; Earthquakes ; Emergency Medical Services ; Humans ; Public Health

Chorionic Villi ; metabolism ; pathology ; ultrastructure ; Diabetes, Gestational ; metabolism ; pathology ; Female ; Glucose ; metabolism ; Glycogen ; metabolism ; Humans ; Lipids ; analysis ; Microscopy, Electron, Scanning ; Microscopy, Electron, Transmission ; Placenta ; metabolism ; pathology ; ultrastructure ; Pregnancy

Objective To develop a method to produce leukoreduced platelet concentrates(LR-PCs) from pooled buffy coats in additive solution(a mixture of solutions for medical use).Methods LR-PCs were made from 6 pooled buffy coats(12 whole-blood units) and 220g additive solution,including 90% multiple electrolytes injection solution,8% ACD-A and 2% 50g/L NaHCO3 injection solution.After centrifugation,the PCs were leukoreduced with a filter and stored in a 600ml platelet storage bag.LR-PCs were prepared in a closed system.Results Routinely produced LR-PCs(n=30) contained(2.96?0.31)?1011 platelets with a volume of(270? 32)ml.The WBC and RBC count were(1.3?0.2)?106 and(5.8?1.1)?109 per unit,respectively.The CD62P expression was(22.5? 10.6)%.After 8-day storage,the in vitro quality of LR-PCs,including pH,hypotonic shock response(HSR) and CD62P expression were 7.14?0.04,(54.0?8.2)% and(45.7?13.8)%,respectively.Conclusion In terms of the in vitro quality of LR-PCs,the method of preparing LR-PCs from pooled buffy coats in mixing solutions is feasible.

Objective To investigate the effect of PARP inhibitor 5-AIQ on PARP/NF-?B P65 complex and the NF-?B activity in murine colon carcinoma CT26 cells.Methods The murine colon carcinoma CT26 cells were treated with 5-AIQ in vitro.The expressions of PARP and NF-?B P65 were analyzed by Western Blot.The PARP/NF-?B P65 complex was analyzed by co-immunoprecipitation.The NF-?B binding activity was detected by electrophoretic mobility shift assay(EMSA).Results Compared with 5-AIQ-untreated group,the expressions of PARP and NF-?B P65 were markedly decreased in 5-AIQ-treated colon carcinoma CT26 cell groups(P

Objective To investigate the expression of human leukocyte antigen-G5 (HLA-G5) in healthy Chinese people and the recipients of renal and liver transplantation. The regulating mechanism of the expression of HLA-G5 was discussed by comparing the expression of HLA-G5 in the healthy people with that in renal and liver transplantation recipients. Furthermore, the changing regularity with time was studied by kinesis supervising the expression of HLA-G5 in renal and liver transplantation recipients. Methods The peripheral blood samples (3ml) from 30 health people, 50 recipients of liver transplantation (liver function was stable 3 months after liver transplantation) and 50 recipients of renal transplantation (renal function was stable 3 months after renal transplantation) were collected. Peripheral blood samples were also collected in same amount from 33 recipients of renal and liver transplantation before operation and 1, 4 and 12 weeks and 1 year after operation. The HLA-G5 of all serum samples was analyzed by ELISA. Results For 30 healthy people, the OD value of HLA-G5 in 28 people was below 0.5, for which the contents were defined as 0.0ng/ml according to standard and the contents for the other 2 people were 8ng/ml and 9ng/ml, respectively. 16 of 50 recipients undergone liver transplantation were positive for the expression of HLA-G5, the positive ratio was 32%. The contents in 4 recipients were higher than 30ng/ml. 10 of 50 recipients of renal transplantation were positive in the expression of HLA-G5, the positive ratio was 20%. The contents in one recipient were higher than 25ng/ml. The average contents in sera of healthy people, recipients of liver or renal transplantation were 0.56?0.20ng/ml, 8.34?1.50ng/ml and 3.26?0.25ng/ml, respectively. For 33 recipients of liver or renal transplantation, the expression of HLA-G5 was detected by ELISA, and it was found that one recipient the expression of HLA-G5 was positive before operation and within 1 week after operation; expression of HLA-G5 was positive in 4 recipients within 4 weeks after operation; expression of HLA-G5 was positive within 12 weeks after operation in 12 recipients; and the expression of HLA-G5 was positive within 1 year after operation in 11 recipients. Conclusion The expression of HLA-G5 in healthy people is low. There are correlation between the expression of HLA-G5 and immunotolerance to transplants. In minor rejection condition after transplantation, there are different expression levels of HLA-G5, and it is higher after liver transplantation than!renal transplantation. The time for expression of HLA-G5 corresponds with the time for mRNA of HLA-G5 transcription into protein, and it is about 15-60 days, with 60 days as the peak time.